HRP20250254T1 - Derivati 2‑aminopiridina ili 2‑aminopirimidina kao inhibitori kinaze ovisne o ciklinima - Google Patents
Derivati 2‑aminopiridina ili 2‑aminopirimidina kao inhibitori kinaze ovisne o ciklinima Download PDFInfo
- Publication number
- HRP20250254T1 HRP20250254T1 HRP20250254TT HRP20250254T HRP20250254T1 HR P20250254 T1 HRP20250254 T1 HR P20250254T1 HR P20250254T T HRP20250254T T HR P20250254TT HR P20250254 T HRP20250254 T HR P20250254T HR P20250254 T1 HRP20250254 T1 HR P20250254T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- fluoroalkyl
- cancer
- substituted
- pharmaceutically acceptable
- Prior art date
Links
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 title 2
- 150000005006 2-aminopyrimidines Chemical class 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 32
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 23
- 150000001875 compounds Chemical class 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 20
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 9
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 8
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 7
- 206010006187 Breast cancer Diseases 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 208000026310 Breast neoplasm Diseases 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 239000013543 active substance Substances 0.000 claims 3
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims 2
- 108010081348 HRT1 protein Hairy Proteins 0.000 claims 2
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 2
- 125000002393 azetidinyl group Chemical group 0.000 claims 2
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 2
- KSCSDVHAZVSGAW-XHBKTUGNSA-N (3R,4R)-4-[[5-chloro-4-[7-fluoro-2-[(1R)-1-hydroxyethyl]-3-propan-2-ylbenzimidazol-5-yl]pyrimidin-2-yl]amino]-1-methylsulfonylpiperidin-3-ol Chemical group ClC=1C(=NC(=NC=1)N[C@H]1[C@@H](CN(CC1)S(=O)(=O)C)O)C=1C=C(C2=C(N(C(=N2)[C@@H](C)O)C(C)C)C=1)F KSCSDVHAZVSGAW-XHBKTUGNSA-N 0.000 claims 1
- QYJLBHRAPDJOSO-NVXWUHKLSA-N (3S,4R)-4-[[5-chloro-4-[7-fluoro-2-(2-hydroxypropan-2-yl)-3-propan-2-ylbenzimidazol-5-yl]pyrimidin-2-yl]amino]oxan-3-ol Chemical group ClC=1C(=NC(=NC=1)N[C@@H]1CCOC[C@H]1O)C=1C=C(C2=C(N(C(=N2)C(C)(C)O)C(C)C)C=1)F QYJLBHRAPDJOSO-NVXWUHKLSA-N 0.000 claims 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims 1
- 229940122815 Aromatase inhibitor Drugs 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 1
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 claims 1
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 claims 1
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 229960002932 anastrozole Drugs 0.000 claims 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims 1
- 239000003886 aromatase inhibitor Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 102000015694 estrogen receptors Human genes 0.000 claims 1
- 108010038795 estrogen receptors Proteins 0.000 claims 1
- 229960000255 exemestane Drugs 0.000 claims 1
- 229960002258 fulvestrant Drugs 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000004653 inflammatory breast carcinoma Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 229960003881 letrozole Drugs 0.000 claims 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 claims 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229960001603 tamoxifen Drugs 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862663096P | 2018-04-26 | 2018-04-26 | |
| US201862750454P | 2018-10-25 | 2018-10-25 | |
| US201962826609P | 2019-03-29 | 2019-03-29 | |
| PCT/IB2019/053314 WO2019207463A1 (en) | 2018-04-26 | 2019-04-22 | 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors |
| EP19727502.7A EP3784664B1 (en) | 2018-04-26 | 2019-04-22 | 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20250254T1 true HRP20250254T1 (hr) | 2025-04-11 |
Family
ID=66676856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20250254TT HRP20250254T1 (hr) | 2018-04-26 | 2019-04-22 | Derivati 2‑aminopiridina ili 2‑aminopirimidina kao inhibitori kinaze ovisne o ciklinima |
Country Status (40)
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA125650C2 (uk) | 2016-09-09 | 2022-05-11 | Інсайт Корпорейшн | Регулятори нрk1 на основі похідних піразолопіридину та їх застосування для лікування раку |
| WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
| TW201811799A (zh) | 2016-09-09 | 2018-04-01 | 美商英塞特公司 | 吡唑并嘧啶化合物及其用途 |
| US10800761B2 (en) | 2018-02-20 | 2020-10-13 | Incyte Corporation | Carboxamide compounds and uses thereof |
| WO2019164847A1 (en) | 2018-02-20 | 2019-08-29 | Incyte Corporation | Indazole compounds and uses thereof |
| MD3784664T2 (ro) * | 2018-04-26 | 2025-06-30 | Pfizer | Derivați de 2-amino-piridină sau de 2-amino-pirimidină utilizați ca inhibitori de kinaze dependente de cicline |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
| WO2020180959A1 (en) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
| MX2022001562A (es) | 2019-08-06 | 2022-04-26 | Incyte Corp | Formas solidas de un inhibidor de la cinasa 1 del progenitor hematopoyetico (hpk1). |
| TW202115024A (zh) | 2019-08-14 | 2021-04-16 | 美商英塞特公司 | 作為cdk2 抑制劑之咪唑基嘧啶基胺化合物 |
| IL320609A (en) | 2019-08-26 | 2025-07-01 | Arvinas Operations Inc | Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents |
| US11038699B2 (en) * | 2019-08-29 | 2021-06-15 | Advanced New Technologies Co., Ltd. | Method and apparatus for performing multi-party secure computing based-on issuing certificate |
| AU2020364007A1 (en) | 2019-10-11 | 2022-04-28 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| TW202216131A (zh) | 2020-07-15 | 2022-05-01 | 美商輝瑞大藥廠 | 用於癌症治療之ｋａｔ６抑制劑方法及組合 |
| CA3188821A1 (en) * | 2020-08-13 | 2022-02-17 | Lars ANDERS | Combination therapy |
| CN112028834B (zh) * | 2020-09-11 | 2022-03-29 | 济南悟通生物科技有限公司 | 一种阿贝西利的中间体的合成方法 |
| SI4214202T1 (sl) * | 2020-09-15 | 2025-05-30 | Pfizer Inc. | Trdne oblike inhibitorja cdk4 |
| CN112679522B (zh) * | 2020-12-29 | 2023-02-14 | 南京正济医药研究有限公司 | 一种巴洛沙韦中间体的制备方法 |
| WO2022149057A1 (en) * | 2021-01-05 | 2022-07-14 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
| TW202231282A (zh) * | 2021-02-03 | 2022-08-16 | 大陸商上海拓界生物醫藥科技有限公司 | 稠三環類細胞週期蛋白－依賴性激酶抑制劑及其製備方法和醫藥用途 |
| US20240269073A1 (en) * | 2021-06-07 | 2024-08-15 | Zerion Pharma ApS | Co-amorphous forms for use in cancer therapy |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| IL312650A (en) * | 2021-12-02 | 2024-07-01 | Pfizer | CDK4 inhibitor for cancer treatment |
| WO2023100134A1 (en) | 2021-12-02 | 2023-06-08 | Pfizer Inc. | Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| CN118339157A (zh) * | 2021-12-24 | 2024-07-12 | 江苏恒瑞医药股份有限公司 | 氢化吲哚类化合物、其制备方法及其在医药上的应用 |
| US20250163063A1 (en) * | 2022-01-25 | 2025-05-22 | Kinnate Biopharma Inc. | Inhibitors of cdk4/6 kinase |
| EP4504709A4 (en) * | 2022-04-08 | 2025-12-24 | Biolexis Therapeutics Inc | CDK9 inhibitors |
| JP2025513028A (ja) | 2022-04-08 | 2025-04-22 | バイオレクシス セラピューティクス，インコーポレイティド | Ｃｄｋ９阻害剤 |
| KR20250004015A (ko) * | 2022-04-29 | 2025-01-07 | 베이진 엘티디 | 사이클린 의존성 키나제 저해제로서의 치환된 7-(피리미딘-4-일)퀴놀린-4(1h)-온 화합물 |
| AR129185A1 (es) * | 2022-04-29 | 2024-07-24 | Beigene Ltd | Compuestos de 6-(pirimidin-4-il)quinolina sustituidos como inhibidores de la cinasa dependiente de ciclina |
| WO2024023703A1 (en) | 2022-07-29 | 2024-02-01 | Pfizer Inc. | Dosing regimens comprising a kat6 inhibitor for the treatment of cancer |
| WO2024022487A1 (en) * | 2022-07-29 | 2024-02-01 | Allorion Therapeutics Inc | Aminoheteroaryl kinase inhibitors |
| WO2024027631A1 (zh) | 2022-08-01 | 2024-02-08 | 江苏恒瑞医药股份有限公司 | 一种稠三环类衍生物的晶型及制备方法 |
| CN117645604A (zh) * | 2022-09-05 | 2024-03-05 | 浙江同源康医药股份有限公司 | 用作cdk4激酶抑制剂的化合物及其应用 |
| WO2024066986A1 (zh) * | 2022-09-30 | 2024-04-04 | 楚浦创制（武汉）医药科技有限公司 | 2-氨基嘧啶类化合物及其应用、药用组合物 |
| WO2024201340A1 (en) | 2023-03-30 | 2024-10-03 | Pfizer Inc. | Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof |
| EP4689660A1 (en) | 2023-03-30 | 2026-02-11 | Pfizer Inc. | Kat6a as a predictive biomarker for treatment with a kat6a inhibitor and methods of treatment thereof |
| WO2024220866A1 (en) * | 2023-04-19 | 2024-10-24 | Accutar Biotechnology Inc. | Novel aminopyrimidine derivatives as cyclin-dependent kinase inhibitors |
| EP4719405A1 (en) | 2023-06-02 | 2026-04-08 | Pfizer Inc. | Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer |
| CN121368483A (zh) | 2023-06-02 | 2026-01-20 | 辉瑞公司 | 雌激素受体降解剂与cdk4抑制剂的组合 |
| CN120936609A (zh) * | 2023-07-19 | 2025-11-11 | 浙江同源康医药股份有限公司 | 用作cdk2/4蛋白激酶抑制剂的化合物及其应用 |
| WO2025024388A1 (en) * | 2023-07-21 | 2025-01-30 | Accutar Biotechnology Inc. | Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors |
| CN121127466A (zh) * | 2023-09-05 | 2025-12-12 | 浙江同源康医药股份有限公司 | 用作cdk4激酶抑制剂的化合物及其应用 |
| WO2025078995A1 (en) * | 2023-10-11 | 2025-04-17 | Beigene Switzerland Gmbh | Substituted 6-(pyrimidin-4-yl)quinoline compounds as cyclin dependent kinase inhibitors |
| WO2025104624A1 (en) | 2023-11-14 | 2025-05-22 | Pfizer Inc. | Synthesis of 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1h-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-d-threo-pentitol |
| WO2025141469A1 (en) | 2023-12-26 | 2025-07-03 | Pfizer Inc. | Crystalline form of 2-methoxy-n-{4-methoxy-6-[(1h-pyrazol-1-yl)methyl]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide |
| WO2025157245A1 (en) * | 2024-01-25 | 2025-07-31 | Allorion Therapeutics Inc | Aminoheteroaryl kinase inhibitors |
| WO2025183591A1 (ru) * | 2024-02-29 | 2025-09-04 | Федеральное государственное унитарное предприятие "Всероссийский научно-исследовательский институт автоматики им. Н.Л. Духова" (ФГУП "ВНИИА") | Производные 2н-[1,4]оксазино- и 2h-[1, 4]тиазино[3,2-c]хинолин-3(4h)-онов в качестве ингибиторов атм и dna-pk киназ |
| TW202539674A (zh) * | 2024-03-05 | 2025-10-16 | 大陸商浙江同源康醫藥股份有限公司 | 用作cdk4蛋白激酶抑制劑的化合物及其應用 |
| WO2025202854A1 (en) | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer |
| WO2025202871A1 (en) | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Methods for identifying biomarkers of treatment response and use thereof with a cdk4 inhibitor |
| WO2025202900A1 (en) | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Cdk4 inhibitors for use in the treatment of mantle cell lymphoma |
| CN118440041B (zh) * | 2024-07-02 | 2024-09-27 | 苏州凯瑞医药科技有限公司 | 一种手性4-氨基-3-羟基四氢吡喃的制备方法 |
| WO2026025013A2 (en) | 2024-07-26 | 2026-01-29 | Pfizer Inc. | Combination therapy using cdk4 inhibitors for cancer treatments |
| WO2026052020A1 (zh) * | 2024-09-04 | 2026-03-12 | 浙江同源康医药股份有限公司 | 用作cdk4蛋白激酶抑制剂的化合物及其应用 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| JP2003509412A (ja) | 1999-09-17 | 2003-03-11 | シーオーアール セラピューティクス インコーポレイテッド | Ｘａ因子阻害剤 |
| AU2001250783A1 (en) | 2000-02-29 | 2001-09-12 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| US20040171630A1 (en) | 2001-06-19 | 2004-09-02 | Yuntae Kim | Tyrosine kinase inhibitors |
| GB0308466D0 (en) | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
| PL2256106T3 (pl) | 2003-07-22 | 2015-08-31 | Astex Therapeutics Ltd | Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3) |
| GB0317127D0 (en) * | 2003-07-22 | 2003-08-27 | Astex Technology Ltd | Pharmaceutical compounds |
| WO2006038001A1 (en) | 2004-10-06 | 2006-04-13 | Celltech R & D Limited | Aminopyrimidine derivatives as jnk inhibitors |
| US7855205B2 (en) * | 2004-10-29 | 2010-12-21 | Janssen Pharmaceutica Nv | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| JP2010501567A (ja) * | 2006-08-24 | 2010-01-21 | ノバルティス アクチエンゲゼルシャフト | 代謝系、心血管系および他の障害の処置のためのステアロイル−ＣｏＡ不飽和化酵素（ＳＣＤ）阻害剤としての２−（ピラジン−２−イル）−チアゾールおよび２−（１Ｈ−ピラゾール−３−イル）チアゾール誘導体ならびに関連化合物 |
| US8378387B2 (en) | 2008-03-04 | 2013-02-19 | Nec Corporation | Field effect transistor and method of manufacturing the same |
| TWI546290B (zh) | 2008-06-27 | 2016-08-21 | 賽基艾維洛米斯研究股份有限公司 | 雜芳基化合物及其用途 |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| EP2379527A1 (en) | 2008-12-19 | 2011-10-26 | F. Hoffmann-La Roche AG | Pyrimidin- 2 -ylamino derivatives and their use to treat inflammation |
| JO2885B1 (en) | 2008-12-22 | 2015-03-15 | ايلي ليلي اند كومباني | Protein kinase inhibitors |
| EP2475667A1 (en) | 2009-09-10 | 2012-07-18 | F. Hoffmann-La Roche AG | Inhibitors of jak |
| CA2798325A1 (en) | 2010-05-13 | 2011-11-17 | Amgen Inc. | Heteroaryloxyheterocyclyl compounds as pde10 inhibitors |
| WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| JO3300B1 (ar) | 2012-06-06 | 2018-09-16 | Novartis Ag | مركبات وتركيبات لتعديل نشاط egfr |
| TW201444820A (zh) * | 2013-03-13 | 2014-12-01 | Abbvie Inc | 吡啶ｃｄｋ９激酶抑制劑 |
| AR093580A1 (es) | 2013-08-30 | 2015-06-10 | Ptc Therapeutics Inc | Inhibidores bmi-1 de pirimidina sustituidos |
| AU2014337067B2 (en) | 2013-10-18 | 2019-01-24 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of proliferative diseases |
| KR102379517B1 (ko) | 2013-12-30 | 2022-03-25 | 제넨테크, 인크. | 세린/트레오닌 키나아제 억제제 |
| CN106458990B (zh) | 2014-04-04 | 2019-06-07 | 希洛斯医药品股份有限公司 | 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂 |
| MY187555A (en) | 2014-07-24 | 2021-09-29 | Beta Pharma Inc | 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof |
| CN105294655B (zh) | 2014-07-26 | 2019-03-15 | 广东东阳光药业有限公司 | Cdk类小分子抑制剂的化合物及其用途 |
| AU2015367977B9 (en) | 2014-12-24 | 2020-02-06 | Lg Chem, Ltd | Biaryl derivative as GPR120 agonist |
| WO2016192630A1 (zh) | 2015-06-01 | 2016-12-08 | 中国科学院上海药物研究所 | 一类具有激酶抑制活性的化合物、制备方法和用途 |
| EP3313530B1 (en) * | 2015-06-26 | 2022-10-05 | Dana Farber Cancer Institute, Inc. | 4,6-pyrimidinylene derivatives and uses thereof |
| CN105111191B (zh) * | 2015-07-21 | 2018-06-08 | 上海皓元生物医药科技有限公司 | 一种用于合成cdk9抑制剂的关键中间体及其制备方法和用途 |
| CN105153119B (zh) * | 2015-09-11 | 2019-01-01 | 广州必贝特医药技术有限公司 | 吡啶嘧啶胺类化合物或吡啶吡啶胺类化合物及其应用 |
| CN106928216A (zh) | 2015-12-31 | 2017-07-07 | 中国科学院上海药物研究所 | 具有erk激酶抑制活性的化合物、其制备方法和用途 |
| WO2017114512A1 (zh) * | 2015-12-31 | 2017-07-06 | 上海医药集团股份有限公司 | 含氮稠杂环化合物、制备方法、中间体、组合物和应用 |
| WO2017133701A1 (en) | 2016-02-06 | 2017-08-10 | Shanghai Fochon Pharmaceutical Co., Ltd. | Certain protein kinase inhibitors |
| SG11201900328WA (en) * | 2016-07-13 | 2019-02-27 | Jason Marineau | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| WO2018161033A1 (en) | 2017-03-02 | 2018-09-07 | Wright, Adrian | Small molecule ire1-alpha inhibitors |
| EP3686196B1 (en) | 2017-09-20 | 2024-06-12 | Hangzhou Innogate Pharma Co., Ltd. | Polycyclic compound acting as ido inhibitor and/or ido-hdac dual inhibitor |
| MD3784664T2 (ro) | 2018-04-26 | 2025-06-30 | Pfizer | Derivați de 2-amino-piridină sau de 2-amino-pirimidină utilizați ca inhibitori de kinaze dependente de cicline |
-
2019
- 2019-04-22 MD MDE20210192T patent/MD3784664T2/ro unknown
- 2019-04-22 GE GEAP201915475A patent/GEP20227433B/en unknown
- 2019-04-22 RU RU2020134811A patent/RU2762557C1/ru active
- 2019-04-22 MA MA52360A patent/MA52360B1/fr unknown
- 2019-04-22 MX MX2020011294A patent/MX2020011294A/es unknown
- 2019-04-22 PE PE2020001635A patent/PE20201202A1/es unknown
- 2019-04-22 EP EP19727502.7A patent/EP3784664B1/en active Active
- 2019-04-22 FI FIEP19727502.7T patent/FI3784664T3/fi active
- 2019-04-22 SG SG11202009992VA patent/SG11202009992VA/en unknown
- 2019-04-22 KR KR1020237036862A patent/KR102661053B1/ko active Active
- 2019-04-22 KR KR1020207033931A patent/KR102596598B1/ko active Active
- 2019-04-22 GE GEAP202215475A patent/GEAP202215475A/en unknown
- 2019-04-22 CN CN201980042382.5A patent/CN112313219B/zh active Active
- 2019-04-22 AU AU2019259653A patent/AU2019259653B2/en active Active
- 2019-04-22 BR BR112020021689-5A patent/BR112020021689B1/pt active IP Right Grant
- 2019-04-22 PL PL19727502.7T patent/PL3784664T3/pl unknown
- 2019-04-22 ES ES19727502T patent/ES3021205T3/es active Active
- 2019-04-22 LT LTEPPCT/IB2019/053314T patent/LT3784664T/lt unknown
- 2019-04-22 CR CR20200503A patent/CR20200503A/es unknown
- 2019-04-22 UA UAA202006733A patent/UA126177C2/uk unknown
- 2019-04-22 PT PT197275027T patent/PT3784664T/pt unknown
- 2019-04-22 HU HUE19727502A patent/HUE070823T2/hu unknown
- 2019-04-22 WO PCT/IB2019/053314 patent/WO2019207463A1/en not_active Ceased
- 2019-04-22 CA CA3098283A patent/CA3098283C/en active Active
- 2019-04-22 CN CN202410393724.0A patent/CN118286225A/zh active Pending
- 2019-04-22 JP JP2020560277A patent/JP7089061B2/ja active Active
- 2019-04-22 CU CU2020000070A patent/CU20200070A7/es unknown
- 2019-04-22 DK DK19727502.7T patent/DK3784664T3/da active
- 2019-04-22 SI SI201930918T patent/SI3784664T1/sl unknown
- 2019-04-22 RS RS20250294A patent/RS66650B1/sr unknown
- 2019-04-22 HR HRP20250254TT patent/HRP20250254T1/hr unknown
- 2019-04-23 US US16/391,836 patent/US10766884B2/en active Active
- 2019-04-23 TW TW108114112A patent/TWI740135B/zh active
- 2019-04-24 UY UY0001038196A patent/UY38196A/es not_active Application Discontinuation
- 2019-04-26 PY PY201901932509A patent/PY1932509A/es unknown
-
2020
- 2020-07-29 US US16/942,209 patent/US11220494B2/en active Active
- 2020-10-13 PH PH12020551692A patent/PH12020551692A1/en unknown
- 2020-10-15 IL IL278075A patent/IL278075B2/en unknown
- 2020-10-21 EC ECSENADI202067394A patent/ECSP20067394A/es unknown
- 2020-10-21 CO CONC2020/0013149A patent/CO2020013149A2/es unknown
- 2020-10-22 NI NI202000072A patent/NI202000072A/es unknown
- 2020-10-23 CL CL2020002748A patent/CL2020002748A1/es unknown
- 2020-10-23 DO DO2020000191A patent/DOP2020000191A/es unknown
- 2020-11-06 ZA ZA2020/06944A patent/ZA202006944B/en unknown
-
2021
- 2021-12-07 US US17/544,303 patent/US12378232B2/en active Active
-
2022
- 2022-06-09 JP JP2022093962A patent/JP2022120096A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20250254T1 (hr) | Derivati 2‑aminopiridina ili 2‑aminopirimidina kao inhibitori kinaze ovisne o ciklinima | |
| JP2021522275A5 (https=) | ||
| JP2016534134A5 (https=) | ||
| JP2021512166A5 (https=) | ||
| JP2014524934A5 (https=) | ||
| JP2020517616A5 (https=) | ||
| JP2012523457A5 (https=) | ||
| JPWO2019207463A5 (https=) | ||
| RU2013147744A (ru) | Дозированная лекарственная форма для перорального применения | |
| CN107548391A (zh) | 嘧啶或吡啶类化合物、其制备方法和医药用途 | |
| RU2018137687A (ru) | Фармацевтические комбинации для лечения злокачественной опухоли | |
| JP2019514854A5 (https=) | ||
| HRP20151410T1 (hr) | Derivati pikolinamida kao inhibitori kinaze | |
| RU2006147307A (ru) | Производные 3-карбамоил-2-пиридона | |
| AR048669A1 (es) | Derivados biciclicos de bisamida | |
| AR061584A1 (es) | Uso de 2-aminotetralinas sustituidas para la fabricacion de un medicamento para la prevencion, alivio y/o tratamiento de diversos tipos de dolor | |
| HRP20221018T1 (hr) | Liječenje katapleksije | |
| JP2013531031A5 (https=) | ||
| RU2018147263A (ru) | Фторированные 2-амино-4-(замещенные амино)фенилкарбаматные производные | |
| PE20140918A1 (es) | Compuestos de benzoxepina inhibidores de la pi3k | |
| MX2016014574A (es) | El uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de mama triple-negativo. | |
| RU2017118165A (ru) | Ингибиторы энхансера гомолога 2 zestes | |
| PE20181017A1 (es) | Compuestos heteroarilo y su uso como farmacos terapeuticos | |
| JP2014528464A5 (https=) | ||
| FI3546462T3 (fi) | Uusi oksoisokinoliinijohdannainen |